A collaboration agreement for the use of the NLAB drug delivery platforms has been signed with Zentiva, a pharmaceutical company operating in Europe and beyond. The aim of this collaboration agreement is to simplify the contract process for future product-specific agreements.
The agreement gives Zentiva the right to use the NLAB drug delivery platforms for multiple drug development projects. Project specific agreements will be signed separately under this collaboration agreement.
” We first met Zentiva during BIO-Europe in 2019. Since then, we have had a continuous dialogue as they see substantial potential in our drug delivery platforms for several of their development projects. With this agreement in place, we now look forward to future collaborations”, says Andreas Bhagwani, CEO of Nanologica.
Zentiva is a producer of high-quality and affordable medicines, serving people in Europe and beyond. The Company headquartered in Prague, Czech Republic has a network of productions sites and employs more than 4 500 employees.
For further information, please contact:
Johanna Johansson, IR Nanologica
Ph: +46 72 211 21 90 or e-mail: firstname.lastname@example.org
About Nanologica AB (publ)
Nanologica was founded in 2004 and is a nanotechnology company developing nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, and type of porosity of silica particles. This knowledge is applied within drug development and chromatography (a separation technique used in drug development and drug production). The company’s mission is to contribute to better and cheaper treatments for patients worldwide through the technology platform NLAB Silica™. Nanologica’s stock (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.